An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse

Roche

Status: Completed

Conditions: Glioblastoma Multiforme

Study type: Observational

Funder types: Industry

Identifiers

NCT01618747

ML25550

Details and patient eligibility

About

This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults patients, >/= 18 years of age
• Histologically confirmed glioblastoma multiforme in first or second relapse

Exclusion criteria

• Patients not qualifying for Avastin treatment as per local label

Trial design

20 participants in 1 patient group

Cohort